Panzomic 40
Pantoprazole Sodium IP equivalent to Pantoprazole 40 mg
Rx GastroenterologyRabgrip DSR
Rabgrip DSR
Rabeprazole Sodium IP (as enteric coated) 20 mg + Domperidone IP (as sustained release) 30 mg
20 mg + 30 mg
Indications
- Symptomatic gastro-oesophageal reflux disease, both erosive and non-erosive
- Duodenal ulcer and benign gastric ulcer accompanied by nausea or vomiting
- Dyspepsia with early satiety, bloating and delayed gastric emptying
- Night-time and breakthrough acid symptoms, where a rapidly activated proton pump inhibitor is preferred
- Acid-related symptoms in patients taking other medicines that compete for CYP2C19 metabolism
Contraindications
- Hypersensitivity to rabeprazole, to other substituted benzimidazoles, or to domperidone
- Pregnancy and breastfeeding, where this combination is not recommended
- Cardiac risk arising from the domperidone component: existing QT prolongation, hypokalaemia or hypomagnesaemia, bradyarrhythmia, or heart failure – 30 mg per capsule represents meaningful domperidone exposure
- Co-prescription with other QT-prolonging drugs or with potent CYP3A4 inhibitors
- Moderate to severe hepatic impairment
- Gastrointestinal bleeding, mechanical obstruction or perforation, where increasing motility is unsafe
- Prolactin-secreting pituitary tumour
Side effects
- Diarrhoea, abdominal pain, flatulence, nausea and dry mouth
- Headache, dizziness and disturbed sleep
- Hyperprolactinaemia from domperidone, presenting as galactorrhoea, gynaecomastia or amenorrhoea
- QT-interval prolongation and, rarely, ventricular arrhythmia – the risk is higher in older patients, at greater domperidone exposure, and where potassium or magnesium levels are low
- With extended proton pump inhibitor therapy: hypomagnesaemia, vitamin B12 depletion, enteric infection and increased fracture risk
Important: This information is provided for educational purposes only and is not a substitute for professional medical advice. Please consult a Registered Medical Practitioner before starting, stopping, or changing any medication. Manufactured and marketed under Indian DCGI regulations.
Product information sheet
Frequently asked questions
What is Rabgrip DSR capsule used for?
Rabgrip DSR is prescribed for acid-related disorders in which motility symptoms are also present: reflux disease with regurgitation and bloating, gastric or duodenal ulcer with nausea, and dyspepsia where the stomach empties slowly. The rabeprazole component reduces acid production and the sustained-release domperidone component improves gastric emptying and settles nausea.
What is the difference between Rabgrip DSR and a pantoprazole-domperidone DSR capsule?
The domperidone half is the same idea in both. The difference lies in the acid blocker. Rabeprazole is activated faster and across a broader pH range than pantoprazole, and it is metabolised largely by a non-enzymatic route rather than depending on CYP2C19, so its effect is more consistent between patients and less influenced by drugs that share that enzyme. Pantoprazole-based combinations remain a widely used alternative; the choice is your physician's.
Does Rabgrip DSR affect the heart?
The domperidone in Rabgrip DSR can prolong the QT interval, and rare cases of serious ventricular arrhythmia have been reported with domperidone, particularly in older patients, at higher exposure, and when potassium or magnesium levels are low. It should be avoided in known QT abnormality, cardiac rhythm disorders and heart failure, and alongside other QT-prolonging drugs or strong CYP3A4 inhibitors. Report palpitations or fainting to your physician immediately.
Related Products
More from the same therapeutic area.